Published in J Transl Med on April 27, 2017
Personalized or Precision Medicine? The Example of Cystic Fibrosis. Front Pharmacol (2017) 0.75
A CFTR potentiator in patients with cystic fibrosis and the G551D mutation. N Engl J Med (2011) 8.73
CFTR as a cAMP-dependent regulator of sodium channels. Science (1995) 6.50
Effect of VX-770 in persons with cystic fibrosis and the G551D-CFTR mutation. N Engl J Med (2010) 6.23
Lumacaftor-Ivacaftor in Patients with Cystic Fibrosis Homozygous for Phe508del CFTR. N Engl J Med (2015) 5.51
Cystic fibrosis pulmonary guidelines: chronic medications for maintenance of lung health. Am J Respir Crit Care Med (2007) 4.34
Functional repair of CFTR by CRISPR/Cas9 in intestinal stem cell organoids of cystic fibrosis patients. Cell Stem Cell (2013) 3.97
Correction of the F508del-CFTR protein processing defect in vitro by the investigational drug VX-809. Proc Natl Acad Sci U S A (2011) 3.87
Results of a phase IIa study of VX-809, an investigational CFTR corrector compound, in subjects with cystic fibrosis homozygous for the F508del-CFTR mutation. Thorax (2011) 2.84
A two-year randomized, placebo-controlled trial of dornase alfa in young patients with cystic fibrosis with mild lung function abnormalities. J Pediatr (2001) 2.78
Clinical mechanism of the cystic fibrosis transmembrane conductance regulator potentiator ivacaftor in G551D-mediated cystic fibrosis. Am J Respir Crit Care Med (2014) 2.63
Effect of genotype on phenotype and mortality in cystic fibrosis: a retrospective cohort study. Lancet (2003) 2.36
Long-term multicentre randomised controlled study of high frequency chest wall oscillation versus positive expiratory pressure mask in cystic fibrosis. Thorax (2013) 2.20
Cystic Fibrosis Foundation evidence-based guidelines for management of infants with cystic fibrosis. J Pediatr (2009) 2.16
Inhaled phosphodiesterase type 5 inhibitors restore chloride transport in cystic fibrosis mice. Eur Respir J (2010) 2.14
A pilot clinical trial of oral sodium 4-phenylbutyrate (Buphenyl) in deltaF508-homozygous cystic fibrosis patients: partial restoration of nasal epithelial CFTR function. Am J Respir Crit Care Med (1998) 2.08
Repeated nebulisation of non-viral CFTR gene therapy in patients with cystic fibrosis: a randomised, double-blind, placebo-controlled, phase 2b trial. Lancet Respir Med (2015) 1.98
Comparison of the clinical manifestations of cystic fibrosis in black and white patients. J Pediatr (1998) 1.97
Ataluren for the treatment of nonsense-mutation cystic fibrosis: a randomised, double-blind, placebo-controlled phase 3 trial. Lancet Respir Med (2014) 1.96
Defining DIOS and constipation in cystic fibrosis with a multicentre study on the incidence, characteristics, and treatment of DIOS. J Pediatr Gastroenterol Nutr (2010) 1.86
Efficacy and safety of ivacaftor in patients aged 6 to 11 years with cystic fibrosis with a G551D mutation. Am J Respir Crit Care Med (2013) 1.73
A comparison of the efficacy and tolerance of pancrelipase and placebo in the treatment of steatorrhea in cystic fibrosis patients with clinical exocrine pancreatic insufficiency. Am J Gastroenterol (2000) 1.68
Combined effects of VX-770 and VX-809 on several functional abnormalities of F508del-CFTR channels. J Cyst Fibros (2014) 1.59
Cystic fibrosis: a 2002 update. J Pediatr (2002) 1.51
Long-term benefits of inhaled tobramycin in adolescent patients with cystic fibrosis. Chest (2002) 1.46
Safety, efficacy and convenience of tobramycin inhalation powder in cystic fibrosis patients: The EAGER trial. J Cyst Fibros (2010) 1.37
Effect of hypertonic saline, amiloride, and cough on mucociliary clearance in patients with cystic fibrosis. Am J Respir Crit Care Med (1996) 1.33
Screening for five mutations detects 97% of cystic fibrosis (CF) chromosomes and predicts a carrier frequency of 1:29 in the Jewish Ashkenazi population. Am J Hum Genet (1992) 1.32
Specific rescue of cystic fibrosis transmembrane conductance regulator processing mutants using pharmacological chaperones. Mol Pharmacol (2006) 1.26
A small-molecule modulator interacts directly with deltaPhe508-CFTR to modify its ATPase activity and conformational stability. Mol Pharmacol (2009) 1.21
Inhibition of airway proteases in cystic fibrosis lung disease. Eur Respir J (2008) 1.17
Synthetic aminoglycosides efficiently suppress cystic fibrosis transmembrane conductance regulator nonsense mutations and are enhanced by ivacaftor. Am J Respir Cell Mol Biol (2014) 1.10
Targeting autophagy as a novel strategy for facilitating the therapeutic action of potentiators on ΔF508 cystic fibrosis transmembrane conductance regulator. Autophagy (2012) 1.08
Ivacaftor for the treatment of patients with cystic fibrosis and the G551D mutation: a systematic review and cost-effectiveness analysis. Health Technol Assess (2014) 1.00
Guidelines for the diagnosis and management of distal intestinal obstruction syndrome in cystic fibrosis patients. J Cyst Fibros (2011) 0.94
∆F508 CFTR interactome remodelling promotes rescue of cystic fibrosis. Nature (2015) 0.90
Pharmacologic approaches to correcting the basic defect in cystic fibrosis. N Engl J Med (2003) 0.89
Macromolecular interactions and ion transport in cystic fibrosis. Am J Respir Crit Care Med (2004) 0.87
A novel treatment of cystic fibrosis acting on-target: cysteamine plus epigallocatechin gallate for the autophagy-dependent rescue of class II-mutated CFTR. Cell Death Differ (2016) 0.83
Effects of salmeterol on arterial oxyhemoglobin saturations in patients with cystic fibrosis. Pediatr Pulmonol (2002) 0.82
[Cystic fibrosis] J Pediatr (Rio J) (1998) 0.79
Meconium ileus equivalent in children and adults. Am J Gastroenterol (1994) 0.79
Longitudinal cystic fibrosis care. Clin Pharmacol Ther (2012) 0.79
Pharmacokinetics and tolerability of oral sildenafil in adults with cystic fibrosis lung disease. J Cyst Fibros (2014) 0.77